1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > HIV-Associated Lipodystrophy Syndrome – Pipeline Review, H1 2013

HIV-Associated Lipodystrophy Syndrome – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 47 pages

HIV-Associated Lipodystrophy Syndrome – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'HIV-Associated Lipodystrophy Syndrome - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for HIV-Associated Lipodystrophy Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV-Associated Lipodystrophy Syndrome. HIV-Associated Lipodystrophy Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for HIV-Associated Lipodystrophy Syndrome.
- A review of the HIV-Associated Lipodystrophy Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the HIV-Associated Lipodystrophy Syndrome pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for HIV-Associated Lipodystrophy Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding HIV-Associated Lipodystrophy Syndrome pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

HIV-Associated Lipodystrophy Syndrome - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
HIV-Associated Lipodystrophy Syndrome Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for HIV-Associated Lipodystrophy Syndrome 7
HIV-Associated Lipodystrophy Syndrome Therapeutics under Development by Companies 9
HIV-Associated Lipodystrophy Syndrome Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
HIV-Associated Lipodystrophy Syndrome Therapeutics - Products under Development by Companies 15
HIV-Associated Lipodystrophy Syndrome Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in HIV-Associated Lipodystrophy Syndrome Therapeutics Development 17
Theratechnologies Inc. 17
Aileron Therapeutics, Inc. 18
HIV-Associated Lipodystrophy Syndrome - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
tesamorelin acetate - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
tesamorelin acetate - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
somatropin - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Leptin - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
mecasermin - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
ALRN-5281 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
HIV-Associated Lipodystrophy Syndrome Therapeutics - Drug Profile Updates 34
HIV-Associated Lipodystrophy Syndrome Therapeutics - Discontinued Products 39
HIV-Associated Lipodystrophy Syndrome - Product Development Milestones 40
Featured News and Press Releases 40
Oct 10, 2012: Theratechnologies Provides Follow-up Regulatory Update On Tesamorelin 40
Sep 06, 2012: Aileron Therapeutics Unveils New Therapeutic Drug Program; Appoints Hubert C Chen As Vice President of Clinical Development 41
Jun 22, 2012: Theratechnologies Provides Regulatory Update On Tesamorelin 41
Jun 04, 2012: Theratechnologies Announces Submission Of Marketing Authorization Application For Tesamorelin In Colombia And Venezuela 42
Dec 07, 2011: Theratechnologies To Discontinue COPD Clinical Program And Accelerate Path To Profitability 43
Oct 19, 2011: Theratechnologies Announces Application For Registration Of Tesamorelin In Mexico 43
Aug 31, 2011: Theratechnologies Announces Marketing Authorization Application For Tesamorelin In Brazil 44
Jul 05, 2011: Theratechnologies Announces Filing Of Application For Registration Of Tesamorelin In Israel By Sanofi 44
Jun 06, 2011: Theratechnologies Announces Filing Of European Marketing Authorization Application For Tesamorelin 45
Jun 24, 2010: Theratechnologies Announces Publication Of Combined Tesamorelin Phase III Results In JCEM 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47



List of Tables

Number of Products Under Development for HIV-Associated Lipodystrophy Syndrome, H1 2013 7
Products under Development for HIV-Associated Lipodystrophy Syndrome - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 16
Theratechnologies Inc., H1 2013 17
Aileron Therapeutics, Inc., H1 2013 18
Assessment by Monotherapy Products, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 23
HIV-Associated Lipodystrophy Syndrome Therapeutics - Drug Profile Updates 34
HIV-Associated Lipodystrophy Syndrome Therapeutics - Discontinued Products 39



List of Figures

Number of Products under Development for HIV-Associated Lipodystrophy Syndrome, H1 2013 7
Products under Development for HIV-Associated Lipodystrophy Syndrome - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Pre-Clinical Stage Products, H1 2013 14
Assessment by Monotherapy Products, H1 2013 19
Assessment by Route of Administration, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Molecule Type, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 7 695
  • Industry report
  • December 2015
  • by Firstword Pharma

ipeline drugs are poised to reshape the way doctors treat ulcerative colitis (UC). But where will new therapies fit into the UC treatment paradigm? How will they affect existing brands? And what will ...

Peptide Therapeutics Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020

Peptide Therapeutics Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020

  • $ 7 500
  • Industry report
  • November 2015
  • by Future Market Insight Global & Consulting Pvt Ltd

Future Market Insights offers a 6-year forecast of the global peptide therapeutics market between 2015 and 2020. In terms of value, the market is expected to register a CAGR of 2.9% during the forecast ...

Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth

Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth

  • $ 4 995
  • Industry report
  • November 2015
  • by GBI Research

Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth Summary Prostate Cancer (PC) is a disease predominately of the elderly with 60% of cases diagnosed in ...


Download Unlimited Documents from Trusted Public Sources

Cancer Drug Industry

  • January 2016
    6 pages
  • Cancer Drug  

    Hormone  

    Prostate Cancer  

View report >

Therapy Industry in the US

  • January 2016
  • Therapy  

  • United States  

View report >

Therapy Markets in Australia - Forecast

  • December 2015
    2 pages
  • Pathology  

  • Australia  

    United States  

    North America  

View report >

Nursing Home Industry

3 months ago

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.